ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Presentations & Interviews


 
    Noxopharm 2020 AGM Corporate Update  
 
    CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV  
 
    Noxopharm CMO discusses first patient treated in NOXCOVID trial  
 
    Noxopharm Corporate Presentation September 2020  
 
    Pitt Street Research Noxopharm CEO interview August 2020  
 
    Noxopharm August 2020 EGM Corporate Presentation  
 
    FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours  
 
    Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording  
 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
    Noxopharm Virtual Roadshow Corporate Presentation  
 
    Veyonda® Mode of Action  
 
    Noxopharm Corporate Presentation February 2020  
 
    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
 
    Noxopharm Non-Deal Roadshow Presentation  
 
    Veyonda® - Boosting the effectiveness of radiotherapy  
 
    DARRT-1 Clinical Data Webinar  
 
    NOXOPHARM DARRT-1 Interview Dec 2, 2019  
 
    NOX 2019 AGM webcast  
 
    Noxopharm 2019 AGM Corporate Presentations  
 
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
    Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial  
 
    NOX EGM Chairman's Address and Presentation  
 
    CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results  
 
    Noxopharm (ASX:NOX) 3-year listing anniversary update  
 
    Noxopharm August 2019 Corporate Presentation  
 
    Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA  
 
    Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.  
 
    Noxopharm Corporate Presentation June 2019  
 
    Switzer Daily: How a biotech company could change cancer treatment  
 
    CEO Interview DARRT Program 6-month Interim Results  
 
    Noxopharm Ausbiotech Asia Series March 2019 Presentation  
 
    March 2019 Corporate Presentation  
 
    FNN - Shaw & Partners Investor Event 26.2.19  
 
    St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    2018 Annual General Meeting podcast  
 
    NOX 2018 AGM Presentations  
 
    Noxopharm Releases Latest Corporate Presentation  
 
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
    NOX Corporate Presentation FNN-Shaw&Partners Investor Event  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    Noxopharm CEO Interview Updates the Company's Current Research and Development Program  
 
    Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1  
 
    Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs  
 
    TROG Annual Scientific Meeting - Noxopharm Presentation 21.3.18  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7  
 
    NOX Open Briefing Corporate Presentation  
 
    Noxopharm Limited 2017 AGM Webcast, November 27, 2017  
 
    AGM Presentations  
 
    EGM Presentations  
 
    October 2017 Open Briefing Corporate Presentation  
 
    Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21  
 
    New Corporate Presentation  
 
    Noxopharm Mid- Year Briefing May 2017  
 
    New Corporate Presentation  
 
    Discovery of Idronoxil-C - NOX CEO explains  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    ASX The CEO Sessions - ASX Interview  
 
    ASX The CEO Sessions February 2017 Presentation  
 
    ASX CEO Presentation Feb 2017 slides  
 
    Upcoming Events and Presentations  
 
    Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’  
 
    November 2016 Corporate Presentation  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    Corporate Presentation  
 
    Investor Roadshow Presentation